Meldungen zum Thema Medizin

Abonnieren Sie alle Meldungen zum Thema Medizin

13.07.2018 – 07:09

Syntellix AG

Syntellix AG: Successful selection to the funding program "German Accelerator Life Sciences"

Hannover (ots) - Syntellix successfully passes a multi-stage admission and assessment process - Program offers selected German companies support in entering the US market and is supported by the German Federal Ministry for Economic Affairs and Energy - The United States, by far the largest market for implants ...

11.07.2018 – 21:37

Gerresheimer AG

Gerresheimer extends business model and increases growth forecast

Düsseldorf (ots) - - With the acquisition of Sensile Medical, Gerresheimer is extending its business model in the direction of an Original Equipment Manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers. The purchase price is a ...

Ein Dokument

10.07.2018 – 13:39

Syntellix AG

Top US Investor Steven F. Mayer becomes shareholder of Syntellix and will join Supervisory Board

Hannover (ots) - Important step for company´s North American strategy - Syntellix investor base now extends from Los Angeles to Singapore Syntellix AG, a fast-growing medical technology innovator that is in the process of disrupting the global orthopaedic implant market using patent-protected magnesium technology ...

02.07.2018 – 18:31

UCB Pharma

UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

Brussels (ots/PRNewswire) - - NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa - NEUPRO approval in China reinforces UCB's ongoing commitment to supporting patient value across China and to offering Chinese patients ...

29.06.2018 – 01:02

Astellas Pharma Europe Limited

Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

27.06.2018 – 13:30

Digital Education Holdings

Novel EU study system EDU for human medicine approved

Valletta (ots) - Intensive practical training in high-end hospitals located in students home region accompanied by state-of-the-art online learning - admissions open for students in Germany today "The innovative EDU study model provides the best possible education in clinical medicine to young people with an intrinsic passion for becoming a physician. EDU is thus committed to help shape a fairer and ...

23.06.2018 – 16:13

Novo Nordisk A/S

Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Orlando, Florida (ots/PRNewswire) - Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE) study comparing the ...

23.06.2018 – 16:10

Novo Nordisk A/S

Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI >=25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Orlando, Florida (ots/PRNewswire) - Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults ...

23.06.2018 – 16:07

Novo Nordisk A/S

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Orlando, Florida (ots/PRNewswire) - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of ...

23.06.2018 – 14:05

Novo Nordisk A/S

Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Bagsværd, Denmark (ots/PRNewswire) - Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy® (insulin degludec and liraglutide ...

21.06.2018 – 11:00

Grünenthal Group

Grünenthal, Lead Discovery Center and Max Planck Society enter into a research collaboration on Charcot-Marie-Tooth 1A (CMT1A)

Aachen, Dortmund and Göttingen (ots) - Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited ...

20.06.2018 – 10:01

Ethypharm

Ethypharm Appoints Frédéric MOLIN to Leads Its Corporate Development

St Cloud, France (ots/PRNewswire) - Ethypharm is pleased to welcome Frédéric MOLIN to Ethypharm Group as Executive Vice President Corporate Development. (Logo: https://mma.prnewswire.com/media/708212/Ethypharm_Logo.jpg ) (Photo: https://mma.prnewswire.com/media/708213/Frederic_MOLIN.jpg ) Frédéric MOLIN will be responsible to initiate and lead strategic ...

14.06.2018 – 15:00

Merck KGaA

Merck to Present Data on Mavenclad® and Rebif® in Relapsing Forms of Multiple Sclerosis at EAN

Darmstadt, Germany (ots/PRNewswire) - - 14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets)and Rebif (interferon beta-1a) Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of ...

12.06.2018 – 17:59

OxThera AB

OxThera Announces the Appointment of Dr Alain Munoz to its Board of Directors

Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. "It is my pleasure to welcome Alain to the board of Oxthera," said Dr. Georges Gemayel, Chairman of ...

12.06.2018 – 13:00

Grünenthal Gruppe

Grünenthal Initiates Pivotal Phase III Trials in Complex Regional Pain Syndrome

Aachen, Germany (ots) - Grünenthal announced today that first patients have been enrolled in two trials of the company's pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. ...

11.06.2018 – 09:07

Janssen Pharmaceutica

Janssen to Showcase New Data Across Broad Rheumatology Portfolio and Immunology Pipeline at EULAR 2018

Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...

07.06.2018 – 07:00

UCB Pharma

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases

Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...

05.06.2018 – 14:00

IMI-PainCare

IMI-PainCare: Public-private partnership tackles major challenges in the care of pain patients

Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...

04.06.2018 – 14:16

Merck KGaA

Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an ...

04.06.2018 – 14:01

Merck KGaA

Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)

Chicago (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and ...

03.06.2018 – 14:31

Merck KGaA

Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing Phase II tepotinib study show anti-tumor clinical ...

03.06.2018 – 14:31

Takeda Pharmaceutical Company Limited

Takeda Highlights Favorable Safety Profile of Entyvio® (vedolizumab) Through Comparative Real-World Data Versus TNFalpha-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease

Osaka, Japan (ots/PRNewswire) - Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of ...

01.06.2018 – 12:17

Galderma

Galderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'

Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...

30.05.2018 – 09:03

Merck KGaA

World MS Day 2018: Call for Greater Curiosity to Drive Understanding of the Disease and Future Innovation

Darmstadt, Germany (ots/PRNewswire) - - Launch of #MSInsideOut campaign, aimed at providing a deeper understanding of multiple sclerosis (MS) - Donation to the MS International Federation (MSIF)* of up to EUR20,000 - Shift.ms to Executive Produce a documentary to highlight stories and unique perspectives within the ...

25.05.2018 – 08:01

OstomyCure AS

Significant Achievement for OstomyCure AS and TIES®Solution

Oslo, Norway (ots/PRNewswire) - Approval for multicenter study "TIES-C03" in major university hospitals in Leeds, UK & Umeå, Sweden. OstomyCure AS has achieved an important milestone on the way to making the revolutionary TIES® Solution available to ileostomy patients, a patient population that has not experienced any major improvements in "standard of ...

24.05.2018 – 14:09

European Society for Medical Oncology (ESMO)

ESMO emphasises importance of cancer on global health agenda at WHA

Lugano (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100006433?langid=2 - At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. ESMO advocated the strengthening of health systems to achieve Universal Health Coverage and to ...

24.05.2018 – 08:01

Novo Nordisk A/S

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, ...

12345678910Nächste